NASDAQ · SMMT
Healthcare · Biotechnology
$13.73
Down-$0.60 (-4.19%)
Updated Aug 31, 2026, 12:23 PM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SMMT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning SMMT.
SMMT research
Company profile and research snapshot.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 25, 2026 | Bernstein | Market Perform | — |
| Aug 18, 2026 | HC Wainwright & Co. | Neutral | — |
| Aug 12, 2026 | Leerink Partners | Market Perform | — |
| Jul 24, 2026 | Stifel | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 26, 2026
Summit Therapeutics partner Akeso Phase 3 HARMONi-GI1 trial shows ivonescimab outperforms durvalumab in overall survival for advanced biliary tract cancer.
Benzinga · Aug 26, 2026
Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics (NASDAQ:SMMT) stock rose
Benzinga · Aug 26, 2026
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.
Benzinga · Aug 25, 2026
Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SMMT.
